1. Home
  2. Directory
  3. California
  4. Stanford
  5. Ophthalmology
  6. NPI Profile
  7. Prescriptions 1326541129

BENYAM ZERIHUN KINDE MD,PHD
Prescription History 1326541129
Ophthalmology in Stanford, CA


Quality Rating: 81.31 out of 100 score

NPI Status: Active since March 18, 2018

Contact Information

300 PASTEUR DR
STANFORD, CA
ZIP 94305
Phone: (650) 723-4000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for BENYAM ZERIHUN KINDE MD,PHD, an active Ophthalmology specialist practicing in Stanford, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 93 documented patient claims. Among these therapy options, the most frequently utilized medication is Neomycin-Polymyxin-Dexameth, which accounts for 29 claims alone.

Medication Index

B
E
L
N
No matching medications currently found on file.

Bacitracin-Polymyxin

Generic Formulation: Bacitracin/Polymyxin B SulfateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 113
CA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills40.0
Peer Average Days Supply570
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.5% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $227.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.15

State Avg Cost Per Claim

$15.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat eye infections. This product contains bacitracin and polymyxin, antibiotics that work by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 516
CA State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills52.4
Peer Average Days Supply831
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $340.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.78

State Avg Cost Per Claim

$15.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 26
30-Day Fills 43.9
Days Supply 1,261
CA State Average Benchmarks
Peer Average Claims159.0
Peer Average 30-Day Fills301.1
Peer Average Days Supply8,658
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.6% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $275.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.60

State Avg Cost Per Claim

$21.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 420
CA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply675
Conservative Utilization

This provider writes prescriptions for this formulation 29.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $532.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.35

State Avg Cost Per Claim

$14.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like BENYAM ZERIHUN KINDE MD,PHD provides transparency into local medical care patterns within Stanford, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.